Inhibition of cell death by lens-specific overexpression of bcl-2 in transgenic mice

Developmental Genetics

Volumn 20, Issue 3, 1997, Pages 276-287

  Fromm, Larry ^a,b   Overbeek, Paul A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; bcl 2; Crystallin; Lens; p53; Transgenic

Indexed keywords

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; EPITHELIUM CELL; GENE EXPRESSION REGULATION; IN SITU HYBRIDIZATION; LENS EPITHELIUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RECEPTOR UPREGULATION; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; GENE EXPRESSION; HUMANS; LENS, CRYSTALLINE; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MUS MUSCULUS; SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40;

EID: 0030745877     PISSN: 0192253X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6408(1997)20:3<276::AID-DVG10>3.0.CO;2-6     Document Type: Article

References (63)

1. Alderson LM, Castleberg RL, Harsh IV GR, Louis DN, Henson JW (1995): Human gliomas with wild-type p53 express bcl-2. Cancer Res 55:999-1001.
2. Allsopp TE, Wyatt S, Paterson HF, Davies AM (1993): The proto-oncogene bcl-2 can selectively rescue neurotrophic factor-dependent neurons from apoptosis. Cell 73:295-307.
3. Bissonnette RP, Echeverri FE, Mahboubi A, Green DR (1992): Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359:552-554.
4. Chen J, Flannery JG, LaVail MM, Steinberg RH, Xu J (1996): bcl-2 overexpression reduces apoptotic photoreceptor cell death in three different retinal degenerations. Proc Natl Acad Sci USA 93:7042-7047.
5. Chiou SK, Rao L, White E (1994): Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol 14:2556-2563.
6. Clarke AR, Maandag ER, van Roon M, van der Lugt NMT, van der Valk M, Hooper ML, Berns A, te Riele H (1992): Requirement for a functional Rb-1 gene in murine development. Nature 359:328-330.
7. Cleary ML, Smith SD, Sklar J (1986): Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulm transcript resulting from the t(14; 18) translocation. Cell 47:19-28.
8. Cosulich SC, Green S and Clarke PR (1996): Bcl-2 regulates activation of apoptotic proteases in a cell-free system. Curr Biol 6:997-1005.
9. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, Friend SH. (1990): p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10:5772-5781.
10. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr. CA, Butel JS, Bradley A. (1992): Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221.
11. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KE, Vogelstein B (1993): WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
12. Elledge RM, Lee W-H (1995): Life and death by p53. BioEssays 17:923-930.
13. Ewen M, Xing YE, Lawrence JB, Livingston JM (1991): Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product-related protein. Cell 66:1155-1164.
14. Fanidi A, Harrington EA, Evan GI (1992): Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359:554-556.
15. Fanning E, Knippers R (1992): Structure and function of simian virus 40 large tumor antigen. Annu Rev Biochem 61:55-85.
16. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ (1988): Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531-539.
17. Fromm L, Overbeek PA (1996): Regulation of cyclin and cyclin-dependent kinase gene expression during lens differentiation requires the retinoblastoma protein. Oncogene 12:69-75.
18. Fromm L, Shawlot W, Gunning K, Butel JS, Overbeek PA (1994): The retinoblastoma binding-region of simian virus 40 large T antigen alters cell cycle regulation in lenses of transgenic mice. Mol Cell Biol 14:6743-6754.
19. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R (1991): p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413-5417.
20. Garcia I, Martinou I, Tsujimoto Y, Martinou J-C (1992): Prevention of programmed cell death of sympathetic neurons by the bcl-2 proto-oncogene. Science 258:302-304.
21. Gavrieli Y, Sherman Y, Ben-Sasson SA (1992): Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493-501.
22. Hague A, Moorghen M, Hicks D, Chapman M, Paraskeva C (1994): bcl-2 expression in human colorectal adenomas and carcinomas. Oncogene 9:3367-3370.
23. Hannon GJ, Demetrick D, Beach D (1993): Isolation of the Rb-related p130 through its interaction with CDK2 and cyclins. Genes Dev 7:2378-2391.
24. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993): The p21 cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
25. Hinds P, Finlay C, Levine AJ (1989): Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 62:739-746.
26. Hockenbery DM (1994): bcl-2 in cancer, development and apoptosis. J Cell Sci 18:51-55.
27. Hogan B, Constantini F, Lacy E (1986) "Manipulating the Mouse Embryo: A Laboratory Manual." Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
28. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991): p53 mutations in human cancers. Science 253:49-53.
29. Howes KA, Ransom N, Papermaster DS, Lasudry JG, Albert DM, Windle JJ (1994): Apoptosis or retinoblastoma: Alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev 8:1300-1310.
30. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA (1992): Effects of an Rb mutation in the mouse. Nature 359:295-300.
31. L transgenes and photoreceptor degeneration. Invest Ophthalmol Vis Sci 37:2434-2446.
32. Ko LJ, Prives C (1996): p53: Puzzle and paradigm. Genes Dev 10:1054-1072.
33. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A (1989): High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 9:3982-3991.
34. Lee EY-HP, Chang C-Y, Hu N, Wang Y-CJ, Lai C-C, Herrup K, Lee W-H, Bradley A (1992): Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359:288-294.
35. Levine AJ (1993): The tumor suppressor genes. Annu Rev Biochem 62:623-651.
36. Lowe SW, Ruley HE (1993): Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 7:535-545.
37. Mahon KA, Chepelinsky AB, Khillan JS, Overbeek PA, Piatigorsky J, Westphal H (1987): Oncogenesis of the lens in transgenic mice. Science 235:1622-1628.
38. Maltzman W, Czyzyk L (1984): UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed cells. Mol Cell Biol 4:1689-1694.
39. Marin MC, Hsu B, Meyn RE, Donehower LA, El-Naggar AK, McDonnell TJ (1994): Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene 9:3107-3112.
40. McAvoy JW (1978): Cell division, cell elongation and distribution of α-, β-and δ-crystallins in the rat lens. J Embryol Exp Morphol 44:149-165.
41. McDonnell TJ, Korsmeyer SJ (1991): Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 349:254-256.
42. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, Korsmeyer SJ (1989): bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79-88.
43. Miyashita T, Reed JC (1995): Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene. Cell 80:293-299.
44. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC (1994): Tumor suppressor p53 is a regulator of bcl-2 and Bax gene expression in vitro and in vivo. Oncogene 9:1799-1805.
45. Monaghan P, Amos TA, Dyer MJ, Mason DY, Greaves MF (1992): Ultrastructural localization of bcl-2 protein. J Histochem Cytochem 40:1819-1825.
46. Morgenbesser SD, Williams BO, Jacks T, DePinho RA (1994): p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 371:72-74.
47. Oltvai ZN, Milliman CL, Korsmeyer SJ (1993): bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619.
48. Overbeek PA, Chepelinsky AB, Khillan JS, Piatigorsky J, Westphal H (1985): Lens-specific expression and developmental regulation of the bacterial chloramphenicol acetyltransferase gene driven by the murine αA-crystallin promoter in transgenic mice. Proc Natl Acad Sci USA 82:7815-7819.
49. Pan H, Griep AE (1994): Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: Implications for tumor suppressor gene function in development. Genes Dev 8:1285-1299.
50. Pan H, Griep AE (1995): Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes Dev 9:2157-2169.
51. Piatigorsky J (1981): Lens differentiation in vertebrates: A review of cellular and molecular features. Differentiation 19:134-153.
52. Robinson ML, Overbeek PA, Verran DJ, Grizzle WE, Stockard CR, Friesel R, Maciag T, Thompson JA (1995a): Extracellular FGF-1 acts as a lens differentiation factor in transgenic mice. Development 121:505-514.
53. Robinson ML, MacMillan-Crow LA, Thompson JA, Overbeek PA (1995b): Expression of a truncated FGF receptor results in defective lens development in transgenic mice. Development 121:3959-3967.
54. Seto M, Jaeger U, Hockett BD, Graninger W, Bennett S, Goldman P, Korsmeyer SJ (1988): Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 7:123-131.
55. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J (1992): Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89:4495-4499.
56. Shawlot W, Siciliano MJ, Stallings RL, Overbeek PA (1989): Insertional inactivation of the downless gene in a family of transgenic mice. Mol Biol Med 6:299-307.
57. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B (1995): Bcl-2 and p53 expression during colorectal tumorigenesis. Cancer Res 55:237-241.
58. Sturzbecher HW, Brian R, Addison C, Rudge K, Remm M, Grimaldi M, Keenan E, Jenkins JR (1992): A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7:1513-1523.
59. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T (1994): p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78:703-711.
60. Taketo M, Schroeder AC, Mobraaten LE, Gunning KB, Hanten G, Fox RR, Roderick TH, Stewart CL, Lilly F, Hansen CT, Overbeek PA (1991): FVB/N: An inbred mouse strain preferable for transgenic analysis. Proc Natl Acad Sci USA 88:2065-2069.
61. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993): p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704.
62. Yin X-M, Oltvai ZN, Korsmeyer SJ (1994): BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369:321-323.
63. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M (1991): Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347.